These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21653937)

  • 21. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
    Marty C; Lacout C; Martin A; Hasan S; Jacquot S; Birling MC; Vainchenker W; Villeval JL
    Blood; 2010 Aug; 116(5):783-7. PubMed ID: 20472827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
    Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
    Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W; Kralovics R
    Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
    Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
    Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
    Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
    Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant signal transduction pathways in myeloproliferative neoplasms.
    Kota J; Caceres N; Constantinescu SN
    Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
    Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
    Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Zeeh FC; Meyer SC
    Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
    Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
    Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O; Levine RL
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
    Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
    Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.